|
gptkbp:instanceOf
|
gptkb:disease
leukemia
myeloproliferative neoplasm
|
|
gptkbp:affects
|
humans
|
|
gptkbp:alsoKnownAs
|
gptkb:CML
|
|
gptkbp:associatedWith
|
gptkb:Philadelphia_chromosome
|
|
gptkbp:canProgressTo
|
gptkb:acute_myeloid_leukemia
blast crisis
|
|
gptkbp:causedBy
|
gptkb:BCR-ABL_fusion_gene
|
|
gptkbp:characterizedBy
|
overproduction of myeloid cells
|
|
gptkbp:complication
|
gptkb:anemia
gout
thrombocytopenia
splenic rupture
leukostasis
|
|
gptkbp:diagnosedBy
|
blood test
bone marrow biopsy
cytogenetic analysis
|
|
gptkbp:firstDescribed
|
gptkb:John_Hughes_Bennett
1845
|
|
gptkbp:hasGeneticMarker
|
gptkb:Philadelphia_chromosome
t(9;22)(q34;q11)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
chronic myeloid leukemia
|
|
gptkbp:ICD-10_code
|
C92.1
|
|
gptkbp:incidence
|
1-2 per 100,000 per year
|
|
gptkbp:medianAge
|
55 years
|
|
gptkbp:MeSH_ID
|
gptkb:D015464
|
|
gptkbp:OMIM
|
608232
|
|
gptkbp:originatedIn
|
bone marrow
|
|
gptkbp:period
|
accelerated phase
blast crisis
chronic phase
|
|
gptkbp:prevalence
|
higher in males
rare in children
|
|
gptkbp:prognosis
|
good with treatment
|
|
gptkbp:riskFactor
|
radiation therapy
|
|
gptkbp:symptom
|
gptkb:anemia
fatigue
splenomegaly
weight loss
night sweats
|
|
gptkbp:targetOfDrug
|
gptkb:BCR-ABL_tyrosine_kinase
|
|
gptkbp:treatment
|
gptkb:bosutinib
gptkb:dasatinib
gptkb:ponatinib
gptkb:imatinib
gptkb:nilotinib
stem cell transplantation
tyrosine kinase inhibitors
|
|
gptkbp:bfsParent
|
gptkb:Tasigna
|
|
gptkbp:bfsLayer
|
5
|